Disarming mutant p53 oncogenic function

Pharmacological Research

Volumn 79, Issue , 2014, Pages 75-87

  Girardini, Javier E ^a   Marotta, Carolina ^b,c   Del Sal, Giannino ^b,c  

^a Instituto de Biologia Molecular y Celular de Rosario   (Argentina)

^b Laboratorio Nazionale CIB LNCIB   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Cancer; Mutant p53; Therapeutic strategies

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACETYLCYSTEINE; CC 115; CDB 3; CISPLATIN; COLECALCIFEROL; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; NSC 319726; NU 7441; NUTLIN 3; PEPTIDE 46; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; ROMIDEPSIN; STATHMIN; SYNTHETIC PEPTIDE; TANESPIMYCIN; THIOSEMICARBAZONE DERIVATIVE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GENE FUNCTION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; LIPOSARCOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MISSENSE MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEIOTROPY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

CANCER; MUTANT P53; THERAPEUTIC STRATEGIES;

ANIMALS; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84889674337     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.11.003     Document Type: Article

References (161)

1. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
2. K.H. Vousden, and C. Prives Blinded by the light: the growing complexity of p53 Cell 137 2009 413 431
3. T. Li, N. Kon, L. Jiang, M. Tan, T. Ludwig, and Y. Zhao Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence Cell 149 2012 1269 1283
4. P. Muller, and K.H. Vousden p53 mutations in cancer Nat Cell Biol 15 2013 2 8
5. F. Murray-Zmijewski, E.A. Slee, and X. Lu A complex barcode underlies the heterogeneous response of p53 to stress Nat Rev Mol Cell Biol 9 2008 702 712
6. T. Soussi, and C. Beroud Assessing TP53 status in human tumours to evaluate clinical outcome Nat Rev Cancer 1 2001 233 240 (Pubitemid 33741898)
7. A.M. Goh, C.R. Coffil, and D.P. Lane The role of mutant p53 in human cancer J Pathol 223 2011 116 126
8. R. Brosh, and V. Rotter When mutants gain new powers: news from the mutant p53 field Nat Rev Cancer 9 2009 701 713
9. M. Oren, and V. Rotter Mutant p53 gain-of-function in cancer Cold Spring Harb Perspect Biol 2 2010 a001107 10.1101/cshperspect.a001107
10. W.A. Freed-Pastor, and C. Prives Mutant p53: one name, many proteins Genes Dev 26 2012 1268 1286
11. G.A. Lang, T. Iwakuma, Y. Suh, G. Liu, A. Rao, and J.M. Parant Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome Cell 119 2004 861 872 (Pubitemid 40017691)
12. K.P. Olive, D.A. Tuveson, Z.C. Ruhe, B. Yin, N.A. Willis, and R.T. Bronson Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome Cell 119 2004 847 860 (Pubitemid 40017690)
13. C. Caulin, T. Nguyen, G.A. Lang, T.M. Goepfert, B.R. Brinkley, and W. Cai An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations J Clin Invest 117 2007 1893 1901 (Pubitemid 47036323)
14. T. Terzian, Y. Suh, T. Iwakuma, S.M. Post, M. Neumann, and G.A. Lang The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss Genes Dev 22 2008 1337 1344 (Pubitemid 351717524)
15. M.K. Lee, W.W. Teoh, B.H. Phang, W.M. Tong, Z.Q. Wang, and K. Sabapathy Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo Cancer Cell 22 2012 751 764
16. G. Lozano Mouse models of p53 functions Cold Spring Harb Perspect Biol 2 2010 a001115 10.1101/cshperspect.a001115
17. M. Napoli, J.E. Girardini, S. Piazza, and G. Del Sal Wiring the oncogenic circuitry: Pin1 unleashes mutant p53 Oncotarget 2 2011 654 656
18. H. Song, M. Hollstein, and Y. Xu p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM Nat Cell Biol 9 2007 573 580 (Pubitemid 46696539)
19. H. Solomon, Y. Buganim, I. Kogan-Sakin, L. Pomeraniec, Y. Assia, and S. Madar Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature J Cell Sci 125 2012 3144 3152
20. M. Brázdová, T. Quante, L. Tögel, K. Walter, C. Loscher, and V. Tichý Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences Nucleic Acids Res 37 2009 1486 1500
21. M. Brázdová, L. Navratilova, V. Tichy, K. Nemcova, M. Lexa, and R. Hrtska Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells PLoS ONE 8 2013 e59567
22. Y.A. Suh, S.M. Post, A.C. Elizondo-Fraire, D.R. Maccio, J.G. Jackson, and A.K. El-Naggar Multiple stress signals activate mutant p53 in vivo Cancer Res 71 2011 7168 7175
23. M.V. Blagosklonny, S. Trostel, G. Kayastha, Z.N. Demidenko, L.T. Vassilev, and L.Y. Romanova Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors Cancer Res 65 2005 7386 7392 (Pubitemid 41161272)
24. L. Whitesell, P.D. Sutphin, E.J. Pulcini, J.D. Martinez, and P.H. Cook The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent Mol Cell Biol 1988 1517 1524
25. D. Li, N.D. Marchenko, and U.M. Moll SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis Cell Death Differ 18 2011 1904 1913
26. D. Li, N.D. Marchenko, R. Schulz, V. Fischer, T. Velasco-Hernandez, and F. Talos Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells Mol Cancer Res 9 2011 577 588
27. O.C. Rodriguez, S. Choudhury, V. Kolukula, E.E. Vietsch, J. Catania, and A. Preet Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy Cell Cycle 11 2012 4436 4446
28. C.A. Midgley, and D.P. Lane p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding Oncogene 15 1997 1179 1189 (Pubitemid 27429621)
29. N. Lukashchuk, and K.H. Vousden Ubiquitination and degradation of mutant p53 Mol Cell Biol 27 2007 8284 8295 (Pubitemid 350234240)
30. S.P. Deb Cell cycle regulatory functions of the human oncoprotein MDM2 Mol Cancer Res 1 2003 1009 1016 (Pubitemid 38044976)
31. T. Iwakuma, and G. Lozano MDM2, an introduction Mol Cancer Res 1 2003 993 1000 (Pubitemid 38044974)
32. A. Bouska, and C.M. Eischen Mdm2 affects genome stability independent of p53 Cancer Res 69 2009 1697 1701
33. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, and Z. Filipovic In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848 (Pubitemid 38174664)
34. R.C. Brennan, S. Federico, C. Bradley, J. Zhang, J. Flores-Otero, and M. Wilson Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a Cancer Res 71 2011 4205 4213
35. P. Secchiero, R. Bosco, C. Celeghini, and G. Zauli Recent advances in the therapeutic perspectives of Nutlin-3 Curr Pharm Des 17 2011 569 577
36. I. Ray-Coquard, J.I. Blay, A. Italiano, A. Le Cesne, N. Penel, and J. Zhi Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study Lancet Oncol 13 2012 1133 1140
37. G. Ambrosini, E.B. Sambol, D. Carvajal, L.T. Vassilev, S. Singer, and G.K. Schwartz Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1 Oncogene 26 2007 3473 3481 (Pubitemid 46816754)
38. C.A. Finlay, P.W. Hinds, T.H. Tan, D. Eliyahu, M. Oren, and A.J. Levine Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life Mol Cell Biol 8 1988 531 539
39. M.V. Blagosklonny, J. Toretsky, S. Bohen, and L. Neckers Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90 Proc Natl Acad Sci 93 1996 8379 8383 (Pubitemid 26269566)
40. F.W. King, A. Wawrzynow, J. Höhfeld, and M. Zylicz Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53 EMBO J 20 2001 6297 6305 (Pubitemid 33078703)
41. Y. Peng, L. Chen, C. Li, W. Lu, and J. Chen Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization J Biol Chem 276 2001 40583 40590
42. J.J. Barrot, and T.A. Haystead J Hsp90, an unlikely ally in the war on cancer FEBS J 280 2013 1381 1396
43. M. New, H. Olzscha, and N.B. La Thangue HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6 2012 637 656
44. W. Yan, S. Liu, E. Xu, J. Zhang, Y. Zhang, and X. Chen Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8 Oncogene 32 2013 599 609
45. M. Sonego, D. Schiappacassi, S. Lovisa, A. Dall'Acqua, M. Bagnoli, and F. Lovat Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer EMBO Mol Med 5 2013 707 722
46. S.Y. Shieh, M. Ikeda, and C. Prives DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2 Cell 91 1997 325 334 (Pubitemid 27467963)
47. M. Kapoor, R. Hamm, W. Yan, Y. Taya, and G. Lozano Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation Oncogene 19 2000 358 364 (Pubitemid 30077335)
48. M. Murphy, J. Ahn, K.K. Walker, W.H. Hoffman, R.M. Evans, and A.J. Levine Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a Genes Dev 13 1999 2490 2501 (Pubitemid 29489641)
49. S. Singer, V. Ehemann, A. Brauckhoff, M. Keith, S. Vreden, and P. Schirmacher Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis Hepatology 46 2007 759 768 (Pubitemid 47436122)
50. B. Belleti, and G. Baldasarre Stathmin: a protein with many tasks. New biomarker and potential target in cancer Expert Opin Ther Targets 15 2011 1249 1266
51. A.M. Karst, K. Levanon, S. Duraisamy, J.F. Liu, M.S. Hirsch, and J.L. Hecht Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas Gynecol Oncol 123 2011 5 12
52. R.J. Kurman, and I.-M. Shih Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm Hum Pathol 42 2011 918 931
53. C.N. Landen Jr., M.J. Birrer, and A.K. Sood Early events in the pathogenesis of epithelial ovarian cancer J Clin Oncol 26 2008 995 1005 (Pubitemid 351398093)
54. A.M. Karst, and R. Drapkin Ovarian cancer pathogenesis: a model in evolution J Oncol 2010 2010:932371-84
55. S. Choudhury, V. Kolukula, A. Preet, C. Albanese, and M.L. Avantaggiati Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle 12 2013 1022 1029
56. T. Minamoto, T. Buschmann, H. Habelhah, E. Matusevich, T. Tahara, and A.L. Børresen-Dale Distinct pattern of p53 phosphorylation in human tumors Oncogene 20 2001 3341 3347 (Pubitemid 32588982)
57. M. Matsumoto, M. Furihata, and Y. Ohtsuki Posttranslational phosphorylation of mutant p53 protein in tumor development Med Mol Morphol 39 2006 79 87 (Pubitemid 44576787)
58. S. Di Agostino, S. Strano, V. Emiliozzi, V. Zerbini, M. Mottolese, and A. Sacchi Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation Cancer Cell 10 2006 191 202 (Pubitemid 44311070)
59. J.E. Girardini, M. Napoli, S. Piazza, A. Rustighi, C. Marotta, and E. Radaelli A Pin1/mutant p53 axis promotes aggressiveness in breast cancer Cancer Cell 20 2011 79 91
60. M. Adorno, M. Cordenonsi, M. Montagner, S. Dupont, C. Wong, and B. Hann A Mutant-p53/Smad complex opposes p63 to Empower TGFb-induced metastasis Cell 137 2009 87 98
61. F. Valenti, F. Fausti, F. Biagioni, T. Shay, G. Fontemaggi, and E. Domany Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop Cell Cycle 10 2011 4330 4340
62. N. Syed, H.M. Coley, J. Sehouly, D. Koensgen, A. Mustea, and P. Szlosarek Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer Cancer Res 71 2011 3317 3327
63. L.B. Tan, K.T. Chen, Y.C. Yuan, P.C. Liao, and H.R. Guo Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis World J Urol 28 2010 117 122
64. K. Strebhardt Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Nat Rev Drug Discov 9 2010 643 660
65. D. Yap, J.K. Hsieh, S. Zhong, V. Heath, B. Gusterson, and T. Crook Ser392 phosphorylation regulates the oncogenic function of mutant p53 Cancer Res 64 2004 4749 4754 (Pubitemid 38924517)
66. M. Matsumoto, M. Furihata, A. Kurabayashi, and Y. Ohtsuki Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors Oncol Rep 12 2004 1039 1043
67. M. Matsumoto, M. Furihata, A. Kurabayashi, S. Sasaguri, K. Araki, and H. Hayashi Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma Oncology 67 2004 143 150 (Pubitemid 39482683)
68. M. Furihata, A. Kurabayashi, M. Matsumoto, H. Sonobe, Y. Ohtsuki, and N. Terao Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract J Pathol 197 2002 82 88 (Pubitemid 34450167)
69. R.E. Perez, C.D. Knights, C. Sahu, J. Catania, V.K. Kolukula, and D. Stoler Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway J Cell Physiol 225 2010 394 405
70. C.X. Ma, S. Cai, S. Li, C.E. Ryan, Z. Guo, and W.T. Schaiff Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models J Clin Invest 122 2012 1541 1552
71. S. Origanti, S.R. Cai, A.Z. Munir, L.S. White, and H. Piwnica-Worms Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells Oncogene 32 2013 577 588
72. X. Wang, and R. Simon Identification of potential synthetic lethal genes to p53 using a computational biology approach BMC Med Genom 6 2013 2 10
73. S. Hingorani, L. Wang, A.S. Multani, C. Combs, T.B. Deramaut, and R.H. Hruban Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice Cancer Cell 7 2005 469 483 (Pubitemid 40719130)
74. A.E. Karnoub, and R.A. Weinberg Ras oncogenes: split personalities Nat Rev Mol Cell Biol 9 2008 517 531 (Pubitemid 351881844)
75. R. Ranganathan, K.P. Lu, T. Hunter, and J.P. Noel Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent Cell 89 1997 875 886 (Pubitemid 27513514)
76. M.B. Yaffe, M. Schutkowski, M. Shen, X.Z. Zhou, P.T. Stukenberg, and J.U. Rahfeld Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism Science 278 1997 1957 1960 (Pubitemid 28013239)
77. Y.C. Liou, X.Z. Zhou, and K.P. Lu Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins Trends Biochem Sci 36 2011 501 514
78. E. Yeh, and A.R. Means PIN1, the cell cycle and cancer Nat Rev Cancer 7 2007 381 388 (Pubitemid 46652482)
79. L. Bao, A. Kimzey, G. Sauter, J.M. Sowadski, K.P. Lu, and D.G. Wang Prevalent overexpression of prolyl isomerase Pin1 in human cancers Am J Pathol 164 2004 1727 1737 (Pubitemid 38529775)
80. G. Wulf, P. Garg, Y.C. Liou, D. Iglehart, and K.P. Lu Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis EMBO J 23 2004 3397 3407 (Pubitemid 39209163)
81. P. Zacchi, M. Gostissa, T. Uchida, C. Salvagno, F. Avolio, and S. Voliniak The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults Nature 419 2002 853 857 (Pubitemid 35238573)
82. H. Zheng, H. You, X.Z. Zhou, S.A. Murray, T. Uchida, and G. Wulf The Prolyl isomerase Pin1 is a novel regulator of p53 in genotoxic response Nature 419 2002 849 853 (Pubitemid 35238572)
83. F. Mantovani, F. Tocco, J.E. Girardini, P. Smith, M. Gasco, and X. Lu The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP Nat Struct Mol Biol 14 2007 912 920 (Pubitemid 47525182)
84. T. Uchida, M. Takamiya, M. Takahashi, H. Miyashita, H. Ikeda, and T. Terada Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation Chem Biol 10 2003 15 24 (Pubitemid 36154470)
85. X. Tan, F. Zhou, J. Wan, J. Hang, Z. Chen, and B. Li Pin1 expression contributes to lung cancer: prognosis and carcinogenesis Cancer Biol Ther 9 2010 111 119
86. G. Ayala, D. Wang, G. Wulf, A. Frolov, R. Li, and J. Sowadski The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer Cancer Res 63 2003 6244 6251 (Pubitemid 37255170)
87. K.W. Leung, C.H. Tsai, M. Hsiao, C.J. Tseng, L.P. Ger, and K.H. Lee Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma Oncol Rep 21 2009 1097 1104
88. F. Mantovani, S. Piazza, M. Gostissa, S. Strano, P. Zacchi, and R. Mantovani Pin1 links the activities of c-Abl and p300 in regulating p73 function Mol Cell 14 2004 625 636 (Pubitemid 38739084)
89. E. Yeh, M. Cunningham, H. Arnold, D. Chasse, T. Monteith, and G. Ivaldi A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells Nat Cell Biol 6 2004 308 318 (Pubitemid 38584820)
90. E. Yeh, B.O. Lew, and A.R. Means The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability J Biol Chem 281 2006 241 251 (Pubitemid 43671183)
91. K. Liu, S. Ling, and W.C. Lin TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73 Mol Cell Biol 31 2011 4464 4481
92. K. Liu, N. Bellam, H.Y. Lin, B. Wang, C.R. Stockard, and W.E. Grizzle Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer Mol Cell Biol 29 2009 2673 2693
93. K.W. Colston, S.K. Chander, A.G. Mackay, and R.C. Coombes Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro Biochem Pharmacol 44 1992 693 702
94. K. Nakagawa, Y. Sasaki, S. Kato, N. Kubodera, and T. Okano 22-Oxa-1alpha, 25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer Carcinogenesis 26 2005 1044 1054 (Pubitemid 41214297)
95. S.A. Kerner, R.A. Scott, and J.W. Pike Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3 Proc Natl Acad Sci 86 1989 4455 4459 (Pubitemid 19164573)
96. G. Zinser, K. Packman, and J. Welsh Vitamin D(3) receptor ablation alters mammary gland morphogenesis Development 129 2002 3067 3076 (Pubitemid 34874282)
97. G. Zinser, J.P. Sundberg, and J. Welsh Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis Carcinogenesis 23 2002 2103 2109 (Pubitemid 36109123)
98. S.H. Wang, R.J. Koenig, T.J. Giordano, A. Myc, N.W. Thompson, and J.R. Baker Jr. 1Alpha, 25-dihydroxyvitamin D3 up-regulates Bcl-2 expression and protects normal human thyrocytes from programmed cell death Endocrinology 140 1999 1649 1656 (Pubitemid 29149233)
99. G. Duque, K. El Abdaimi, J.E. Henderson, A. Lomri, and R. Kremer Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways Bone 35 2004 57 64 (Pubitemid 38789148)
100. M. Friedrich, L. Rafi, W. Tilgen, W. Schmidt, and J. Reichrath Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma J Histochem Cytochem 46 1998 1335 1337 (Pubitemid 28487754)
101. M. Friedrich, R. Axt-Fliedner, C. Villena-Heinsen, W. Tilgen, W. Schmidt, and J. Reichrath Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer Histochem J 34 2002 35 40
102. M.O. Sahin, A.E. Canda, K. Yorukoglu, M.U. Mungan, M. Sade, and Z. Kirkali 1,25-Dihydroxyvitamin D(3) receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor? Eur Urol 47 2005 52 57 (Pubitemid 39575718)
103. R.J. Menezes, R.T. Cheney, A. Husain, M. Tretiakova, G. Loewen, and C.S. Johnson Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue Cancer Epidemiol Biomarkers Prev 17 2008 1104 1110
104. P. Stambolsky, Y. Tabach, G. Fontemaggi, L. Weisz, R. Maor-Aloni, and Z. Siegfried Modulation of the vitamin D3 response by cancer-associated mutant p53 Cancer Cell 17 2010 273 285
105. W.A. Freed-Pastor, H. Mizuno, X. Zhao, A. Langerød, S.H. Moon, and R. Rodriguez-Barrueco Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway Cell 148 2012 244 258
106. O. Larsson HMG-CoA reductase inhibitors: role in normal and malignant cells Crit Rev Oncol Hematol 22 1996 197 212 (Pubitemid 26173118)
107. J.W. Clendening, and L.Z. Penn Targeting tumor cell metabolism with statins Oncogene 31 2012 4967 4978
108. C. Gaiddon, M. Lokshin, J. Ahn, T. Zhang, and C. Prives A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain Mol Cell Biol 21 2001 1874 1887 (Pubitemid 32156407)
109. S. Strano, G. Fontemaggi, A. Costanzo, M.G. Rizzo, O. Monti, and A. Baccarini Physical interaction with human tumor-derived p53 mutants inhibits p63 activities J Biol Chem 277 2002 18817 18826 (Pubitemid 34952441)
110. C. Di Como, C. Gaiddon, and C. Prives p73 function is inhibited by tumor-derived p53 mutants in mammalian cells Mol Cell Biol 19 1999 1438 1449 (Pubitemid 29046885)
111. X. Su, D. Chakravarti, M.S. Cho, L. Liu, Y.J. Gi, and Y.L. Lin TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs Nature 467 2010 986 990
112. R. Tomasini, K. Tsuchihara, M. Wilhelm, M. Fujitani, A. Rufini, and C.C. Cheung TAp73 knockout shows genomic instability with infertility and tumor suppressor functions Genes Dev 22 2008 2677 2691
113. P. Muller, P.T. Caswell, B. Doyle, M.P. Iwanicki, E.H. Tan, and S. Karim Mutant p53 drives invasion by promoting integrin recycling Cell 139 2009 1327 1341
114. M.S. Irwin, K. Kondo, M.C. Marin, L.S. Cheng, W.C. Hahn, and W.G. Kaelin Chemosensitivity linked to p73 function Cancer Cell 3 2003 403 410 (Pubitemid 38340308)
115. D. Bergamaschi, M. Gasco, L. Hiller, A. Sullivan, N. Syed, and G. Trigiante p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis Cancer Cell 3 2003 387 402 (Pubitemid 38340307)
116. J.E. Kravchenko, G.V. Ilyinskaya, P.G. Komarov, L.S. Agapova, D.V. Kochetkov, and E. Strom Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway Proc Natl Acad Sci USA 105 2008 6302 6307 (Pubitemid 351758341)
117. S. Di Agostino, G. Cortese, O. Monti, S. Dell'Orso, A. Sacchi, and M. Eisenstein The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs Cell Cycle 7 2008 3440 3447
118. D.P. White, P.T. Caswell, and J.C. Norman alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration J Cell Biol 177 2007 515 525 (Pubitemid 46718279)
119. P.T. Caswell, and J.C. Norman Endocytic transport of integrins during cell migration and invasion Trends Cell Biol 18 2008 257 263
120. P.T. Caswell, M. Chan, A.J. Lindsay, M.W. McCaffrey, D. Boettiger, and J.C. Norman Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments J Cell Biol 183 2008 143 155
121. P. Muller, A.G. Trinidad, P. Timpson, J.P. Morton, S. Zanivan, and P.V. Van den Berghe Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion Oncogene 32 2012 1252 1265
122. M.M. Chaturvedi, B. Sung, V.R. Yadav, R. Kannappan, and B.B. Aggarwal NF-kB addiction and its role in cancer: 'one size does not fit all' Oncogene 30 2011 1615 1630
123. J.A. DiDonato, F. Mercurio, and M. Karim NF-kB and the link between inflammation and cancer Immunol Rev 246 2012 379 400
124. M. Scian, K.E. Stagliano, M.A. Anderson, S. Hassan, M. Bowman, and M.F. Miles Tumor-derived p53 mutants induce NF-kappaB2 gene expression Mol Cell Biol 25 2005 10097 10110 (Pubitemid 41572755)
125. C.A. Vaughan, S. Singh, B. Windle, H.M. Sankala, P.R. Graves, and W. Andrew Yeudall p53 mutants induce transcription of NF-?.B2 in H1299 cells through CBP and STAT binding on the NF-? B2 promoter and gain of function activity Arch Biochem Biophys 518 2012 79 88
126. L. Weisz, A. Damalas, M. Liontos, P. Karakaidos, G. Fontemaggi, and R. Maor-Aloni Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells Cancer Res 67 2007 2396 2401 (Pubitemid 46548921)
127. W.A. Yeudall, C.A. Vaughan, H. Miyazaki, M. Ramamoorthy, M.Y. Choi, and C.G. Chapman Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration Carcinogenesis 33 2012 442 451
128. A. Richmond Nf-kappa B, chemokine gene transcription and tumour growth Nat Rev Immunol 2 2002 664 674 (Pubitemid 37328724)
129. T. Cooks, I.S. Pateras, O. Tarcic, H. Solomon, A.J. Schetter, and S. Wilder Mutant p53 prolongs NF-?B activation and promotes chronic inflammation and inflammation-associated colorectal cancer Cancer Cell 23 2013 634 646
130. S.P. Hussain, P. Amstad, K. Raja, S. Ambs, M. Nagashima, and W.P. Bennett Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease Cancer Res 60 2000 3333 3337 (Pubitemid 30482141)
131. T.A. Ullman, and S.H. Itzkowitz Intestinal inflammation and cancer Gastroenterology 140 2011 1807 1816
132. W. Xue, L. Zender, C. Miething, R.A. Dickings, E. Hernando, and V. Krizhanovsky Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 445 2007 656 660 (Pubitemid 46232886)
133. C.P. Martins, L. Brown-Swigart, and G.I. Evan Modeling the therapeutic efficacy of p53 restoration in tumors Cell 127 2006 1323 1334 (Pubitemid 44960417)
134. A. Ventura, D.G. Kirsch, M.E. McLaughlin, D.A. Tuveson, J. Grimm, and L. Lintault Restoration of p53 function leads to tumour regression in vivo Nature 445 2007 661 665 (Pubitemid 46232887)
135. K.G. Wiman Strategies for therapeutic targeting of the p53 pathway in cancer Cell Death Differ 13 2006 921 926
136. C. Floquet, J. Deforges, J.P. Rousset, and L. Bidou Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides Nucleic Acids Res 39 2011 3350 3362 Ref Type: Journal (Full)
137. K.G. Wiman Pharmacological reactivation of mutant p53: from protein structure to the cancer patient Oncogene 29 2010 4245 4252
138. G. Selivanova Therapeutic targeting of p53 by small molecules Semin Cancer Biol 20 2010 46 56
139. L. Muller, A. Schaupp, D. Walerych, H. Wegele, and J. Buchner Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures J Biol Chem 279 2004 48846 48854 (Pubitemid 39625765)
140. D. Walerych, M.B. Olszewski, M. Gutkowska, A. Helwak, M. Zylicz, and A. Zylicz Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions Oncogene 28 2009 4282 4294
141. V.J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, and P. Chumakov Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat Med 8 2002 282 288 (Pubitemid 34250107)
142. J.M. Lambert, A. Moshfegh, P. Hainaut, K.G. Wiman, and V.J. Bykov Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis Oncogene 29 2010 1329 1338
143. V.J. Bykov, N. Zache, H. Stridh, J. Westman, J. Bergman, and G. Selivanova PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis Oncogene 24 2005 3484 3491 (Pubitemid 40756249)
144. N. Zache, J.M. Lambert, K.G. Wiman, and V.J. Bykov PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53 Cell Oncol 30 2008 411 418
145. H. Nahi, S. Lehmann, L. Mollgard, S. Bengtzen, G. Selivanova, and K.G. Wiman Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion Br J Haematol 127 2004 285 291 (Pubitemid 39468941)
146. H. Nahi, M. Merup, S. Lehmann, S. Bengtzen, L. Mollgard, and G. Selivanova PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion Br J Haematol 132 2006 230 236 (Pubitemid 43381557)
147. D. Walerych, M. Napoli, and G. Del Sal The rebel angel: mutant p53 as the driving oncogene in breast cancer Carcinogenesis 33 2012 2007 2017
148. F.M. Boeckler, A.C. Joerger, G. Jaggi, T.J. Rutherford, D.B. Veprintsev, and A.R. Fersht Targeted rescue of a destabilized mutant of p53 by an in silico screened drug Proc Natl Acad Sci USA 105 2008 10360 10365
149. X. Liu, R. Wilcken, A.C. Joerger, I.S. Chuckowree, J. Amin, and J. Spencer Small molecule induced reactivation of mutant p53 in cancer cells Nucleic Acids Res 41 2013 6034 6044
150. X. Yu, A. Vazquez, A.J. Levine, and D.R. Carpizo Allele-specific p53 mutant reactivation Cancer Cell 21 2012 614 625
151. N. Issaeva, P. Bozko, M. Enge, M. Protopopova, L.G. Verhoef, and M. Masucci Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors Nat Med 10 2004 1321 1328 (Pubitemid 40022713)
152. G. Sorrentino, M. Mioni, C. Giorgi, N. Ruggeri, P. Pinton, and U.M. Moll The prolyl-isomerase Pin1 activates the mitochondrial death program of p53 Cell Death Differ 20 2013 198 202
153. C.Y. Zhao, W. Grinkevich, F. Nikulenkov, W. Bao, and G. Selivanova Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA Cell Cycle 9 2010 1847 1855
154. G. Selivanova, V. Iotsova, I. Okan, M. Fritsche, M. Strom, and B. Groner Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain Nat Med 3 1997 632 638 (Pubitemid 27264972)
155. A. Friedler, L.O. Hansson, D.B. Veprintsev, S.M. Freund, T.M. Rippin, and P.V. Nikolova A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants Proc Natl Acad Sci USA 99 2002 937 942 (Pubitemid 34106614)
156. E. Guida, A. Bisso, C. Fenollar-Ferrer, M. Napoli, C. Anselmi, and J.E. Girardini Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells Cancer Res 68 2008 6550 6558
157. N. Issaeva, A. Friedler, P. Bozko, K.G. Wiman, A.R. Fersht, and G. Selivanova Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide Proc Natl Acad Sci USA 100 2003 13303 13307 (Pubitemid 37444737)
158. E.L. Snyder, B.R. Meade, C.C. Saenz, and S.F. Dowdy Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide PLoS Biol 2 2004 E36
159. C.M. Perou, T. Sørlie, M.B. Eisen, M. Van de Rijn, S.S. Jeffrey, and C.A. Rees Molecular portraits of human breast tumours Nature 406 2000 747 752
160. T. Sørlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, and H. Johnsen Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci 98 2001 10869 10874 (Pubitemid 32878711)
161. A. Langerød, H. Zhao, O. Borgan, J.M. Nesland, I.R.K. Bukholm, and T. Ikdahl TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer Breast Cancer Res 9 2007 R30